

**Shanxi Central Pharmaceutical International Limited**



**RESULTS**

The Board of Directors (the “Board”) of Shanxi Central Pharmaceutical International Limited (the “Company”) is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (the “Group”), which have been reviewed by the Company’s external auditors, for the six months ended 30 November 2001 as follows:

**CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT**

*Six months ended 30 November 2001*

	Notes	<b>30 November 2001 (Unaudited) HK\$'000</b>	30 November 2000 (Unaudited) HK\$'000
TURNOVER	3	<b>148,542</b>	104,215
Cost of sales		<b>(87,087)</b>	(52,979)
Gross profit		<b>61,455</b>	51,236
Other revenue		<b>409</b>	–
Selling and distribution costs		<b>(14,832)</b>	(17,313)
Administrative expenses		<b>(7,732)</b>	(5,379)
Other operating expenses		<b>(3,863)</b>	(16,169)
PROFIT BEFORE TAX	4	<b>35,437</b>	12,375
Tax	5	<b>(6,419)</b>	(2,194)
PROFIT BEFORE MINORITY INTERESTS		<b>29,018</b>	10,181
Minority interests		<b>(326)</b>	(136)
NET PROFIT FROM ORDINARY ACTIVITIES ATTRIBUTABLE TO SHAREHOLDERS		<b>28,692</b>	10,045
EARNINGS PER SHARE	6		
– Basic		<b>HK1.37 cents</b>	HK0.54 cent
– Diluted		<b>N/A</b>	N/A

Other than the net profit from ordinary activities attributable to shareholders, the Group had no recognised gains or losses. Accordingly, a consolidated statement of recognised gains and losses is not presented in the financial statements.